Zharp2-1 is an orally active RIPK2 inhibitor highly relevant to inflammatory bowel disease (IBD); it blocks transcription and release of inflammatory cytokines induced by muramyl dipeptide (MDP) or *Listeria monocytogenes* infection; it effectively alleviates MDP-induced peritonitis in mice and ameliorates DNBS-induced colitis in rats.